Dyadic to Present at Roth Capital New York Conference

Dyadic International, Inc. (AMEX: DIL), a biotechnology
company engaged in the development, manufacture and sale of biological
products, today announced that its President and CEO, Mark Emalfarb,
will present at the Roth Capital Partners New York Conference to be
held on September 7-8, 2005, at the Westin New York at Times Square.
   Dyadic's investor presentation is scheduled for Thursday,
September 8th at 9:00 a.m. EDT. The presentation will be webcast live
and archived online for 30 days on the Investor Relations section of
the company's website at www.dyadic-group.com .

   About Dyadic

   Dyadic International, Inc., is engaged in the development,
manufacture and sale of biological products (proteins, enzymes,
peptides and other bio-molecules), as well as the licensing of its
enabling proprietary technology to business collaborators for the
discovery, development and manufacture of biological products from
genes. Dyadic markets its products and services for applications in
the textile, chemical, agricultural, pulp & paper, pharmaceutical,
biotechnology and other industries, using its proprietary C1 Host
Technology and C1 Expression and Screening Systems for the discovery,
development and production of biological products.

   Cautionary Statement for Forward-Looking Statements

   Statements contained in this press release may contain information
that includes or is based upon certain "forward-looking statements"
relating to our business. For a discussion of the factors that could
cause actual results to vary from these forward-looking statements,
please see our filings from time to time with the Securities and
Exchange Commission, which are available free of charge on the SEC's
web site at http://www.sec.gov, including our Annual Report on Form
10-KSB for the year ended December 31, 2004, which was filed with the
SEC on April 15, 2005, and our Quarterly Report for the quarter ended
June 30, 2005 on Form 10-QSB, which was filed on August 15, 2005.
Except as required by law, we expressly disclaim any intent or
obligation to update any forward-looking statements.